Sarasin & Partners LLP Raises Holdings in Zoetis Inc. $ZTS

Sarasin & Partners LLP increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 1,649,946 shares of the company’s stock after buying an additional 38,367 shares during the quarter. Zoetis makes up 2.3% of Sarasin & Partners LLP’s portfolio, making the stock its 18th largest position. Sarasin & Partners LLP’s holdings in Zoetis were worth $236,041,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Nova Wealth Management Inc. acquired a new position in shares of Zoetis in the first quarter worth $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis during the first quarter valued at $27,000. Saudi Central Bank purchased a new stake in Zoetis during the 1st quarter worth about $29,000. REAP Financial Group LLC increased its position in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares in the last quarter. Finally, NewSquare Capital LLC raised its stake in Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $122.34 on Friday. The company has a market cap of $53.91 billion, a P/E ratio of 20.60, a P/E/G ratio of 2.66 and a beta of 0.97. The firm’s 50 day moving average is $128.86 and its two-hundred day moving average is $144.48. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.40. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be issued a $0.53 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 33.67%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. UBS Group decreased their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. KeyCorp assumed coverage on shares of Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating on the stock. Argus reaffirmed a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Barclays started coverage on Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target on the stock. Finally, Stifel Nicolaus decreased their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. Six equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $160.18.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.